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Abstract
The importance of diseases to mankind is very similar
worldwide. However, social and environmental issues,
not to mention political and individual aspects, affect
the prevalence and management of diseases and their
outcomes. I present a brief and tentative comment to
illustrate that the Latin-American rheumatology
community, despite relevant gains in recent years, has
some challenges to face in order to improve patient
care in our region.
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Recent years have seen great achievements in the
rheumatology field with improvements in disease man-
agement, particularly of rheumatoid arthritis (RA).
Challenges faced by mankind considered as urgencies in
some areas of the globe may be seen otherwise in other re-
gions. Medical issues are no exception. Considering that
priorities vary within specific countries, it is difficult to
evaluate challenges and demands affecting the Latin-
American “subcontinent”. The present comment should
be considered in the context of these limitations, given
that an area comprising 19 countries and the Caribbean
region, with circa 600 million inhabitants, has issues
pertaining to specific countries and relevant variations
within countries may apply [1].
Manpower requirements
The impact of increased life expectancy, ageing popula-
tions, and obesity on the epidemiological importance of
musculoskeletal diseases worldwide justifies an increase
in manpower. The number of rheumatologists in Latin-
America (LA) is considered insufficient compared to de-
veloped countries. In addition, their unequal distribution
worsens the deficit. The vast majority of professionals
Correspondence: arocha@ufc.br
Department of Internal Medicine, Federal University of Ceará, Rua Coronel
Nunes de Melo, 1315, CEP: 60430-270, Rodolfo Teofilo, Fortaleza, CE, Brasil
work in urban areas of major cities, leaving a large
number of individuals without access to rheumatolo-
gists [1, 2]. Data from 2012 showed a mean ratio of
157,809 inhabitants per rheumatologist among 1229
rheumatologists practicing in Brazil. Analyzing the 27
Brazilian States and the Federal District, ratios varied
from 41,383 to 758,786 inhabitants per rheumatologist,
displaying a positive correlation with the local gross do-
mestic product and indices of human development [2].
This uneven distribution in Brazil mimics the situation
in LA; variation from as low as 0.11 up to 4.83 rheuma-
tologists per 100,000 inhabitants in Nicaragua and
Uruguay, respectively—with the rheumatologists work-
ing predominantly in capitals and large cities—has been
reported [1].
The distribution of pediatric rheumatologists is even
more unequal, with 94% working in only 6 out of 19
countries in LA (Argentina, Brazil, Chile, Colombia,
Cuba, and Mexico), with these confined mainly to large
cities [1, 2].
We should remark that the number of rheumatologists
increased in all countries in LA but Chile between 2012
and 2015, with an estimated 4603 specialists in 2015.
This was associated with an increase in the number of
training programs [1] and we may speculate that recent
improvements in the management of autoimmune dis-
eases attracted young physicians to the specialty.
With regard to health care professionals, including
nurses, nutritionists, physiotherapists, and psychologists,
which are all partners in the multidisciplinary team to
better treat rheumatologic patients, training to provide
specialized care rather than increasing their numbers
may be the most urgent need [3].
Medications and health facilities
The unequal manpower distribution is mirrored by
access to medications and health care facilities. Low
income as well as lower literacy have been associated
with delayed and irregular use of biologic disease-
modifying antirheumatic drugs (DMARDS), thereby
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affecting disease outcome [4]. The social burden of the
uneven economic distribution in LA is also reflected in
access to health care, meaning better opportunities for
those with high incomes living in developed areas.
There are claims that the coverage of health systems
varies from 22% in Paraguay to 100% of the population in
Argentina, Brazil, and Cuba [5]. However, a lack of individ-
ual resources to seek institutions, cultural concepts assum-
ing that “rheumatism” is a mild problem and that
rheumatic diseases are “irreversible and incurable” and
caused by the natural ageing process, late referral by pri-
mary care physicians, and a lack of knowledge about a
referral center are some reasons to explain the delay in ini-
tiating RA treatment in Brazil [4]. Despite limitations, RA
treatment has greatly improved, diagnosis is easier, and
access to non-biologic DMARDS is relatively universal in
LA. On the other hand, delays in diagnosing spondyloar-
thropathies and other less prevalent diseases, including
systemic lupus erythematosus and vasculitis, continues to
impose a burden that is undocumented in LA.
Data regarding access to biologic DMARDS are incon-
sistent, which is coupled to large differences among coun-
tries. In Brazil, the public health system provides free
access to any patient with an RA diagnosis that failed
non-biologic DMARDS; these patients are usually treated
in public institutions linked to tertiary rheumatologic
training services. This represents over 50% of the Ministry
of Health’s budget for free medications for chronic
diseases [6, 7]. However, a survey conducted among 212
rheumatologists working in LA showed that biologic
DMARDS are guaranteed to less than 10% of RA patients,
with a major negative socioeconomic impact [5]. The
emergence of biosimilars, proposed to lower costs, came
with worries about regulation of their use given the com-
plex characteristics of the compounds and the availability
of the so-called “intended copies” of biologic DMARDS.
Regulatory issues are still being discussed and they obvi-
ously differ among countries. Rheumatologists and patient
groups should thus work with health authorities in order
to cut prices and increase access without compromising
quality [7, 8].
Challenges regarding non-pharmacological treatments
may have been overlooked. Rehabilitation programs and
facilities, nutrition support, and psychological treatment are
far from ideally offered in LA. Recommendations for osteo-
arthritis (OA) management consider non-pharmacological
strategies as at least as important as medications in provid-
ing pain relief and retarding disease progression. It has even
been suggested that non-pharmacological approaches could
prevent knee OA [9]. Thus, increased health facility cap-
acity, initiatives for patient education, and strategies for
weight control—providing benefits to a high number of in-
dividuals at relatively low cost—are at least as urgently
needed in LA as access to high cost biologic therapies. In
keeping with this assumption, patient-reported outcomes
(PROs) are increasingly relevant to assess the quality and
effectiveness of management strategies and to facilitate de-
cisions about whether or not they should be incorporated
in health care [10]. Health systems in LA may thus improve
assistance and optimize costs using PRO experience.
Research
Collecting specific data on epidemiology across LA is prob-
ably our most urgent need. A recent report on the “global”
burden of hip and knee OA included almost no data from
LA [11] despite the World Health Organization–Inter-
national League of Associations for Rheumatology COP-
CORD (Community-Oriented Program for Control of
Rheumatic Disease) having shown, as expected, that OA is
the most prevalent rheumatic disease in LA [1]. Facing op-
portunities, recent abstracts of the Pan-American League of
Associations of Rheumatology (PANLAR) meeting empha-
sized specificities of cohorts and registry data from LA [12].
The recent outbreak of arbovirus infections in LA, particu-
larly joint involvement in Chikungunya fever [13], is
another example demonstrating the varying interests in
across the globe.
Conclusions
The efforts of rheumatologists working in LA to tackle
their own problems have yielded improvements and we
hope this will be an ever-growing process, resulting in
advances in rheumatology care.
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